Financhill
Buy
73

ACCD Quote, Financials, Valuation and Earnings

Last price:
$7.00
Seasonality move :
-16.57%
Day range:
$6.98 - $7.01
52-week range:
$3.08 - $10.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.23x
P/B ratio:
1.83x
Volume:
1.3M
Avg. volume:
1.3M
1-year change:
-28.1%
Market cap:
$572.6M
Revenue:
$414.3M
EPS (TTM):
-$2.25

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ACCD
Accolade
$142.3M $0.19 14.34% -42.86% $7.03
HQY
HealthEquity
$305.8M $0.72 12.07% 163.76% $114.36
HSTM
HealthStream
$73.5M $0.14 2.98% -- $35.00
SDGR
Schrodinger
$83.2M -$0.38 49.19% -6.58% $32.09
SLP
Simulations Plus
$21.9M $0.26 19.77% 31.43% $49.40
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ACCD
Accolade
$7.01 $7.03 $572.6M -- $0.00 0% 1.23x
HQY
HealthEquity
$84.88 $114.36 $7.3B 77.87x $0.00 0% 6.28x
HSTM
HealthStream
$31.55 $35.00 $960.2M 47.80x $0.03 0.37% 3.30x
SDGR
Schrodinger
$21.80 $32.09 $1.6B -- $0.00 0% 7.63x
SLP
Simulations Plus
$25.56 $49.40 $513.5M 63.89x $0.06 0.94% 6.97x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ACCD
Accolade
40.09% 3.274 66.82% 2.47x
HQY
HealthEquity
33.31% 1.611 11.05% 2.65x
HSTM
HealthStream
-- 0.998 -- 1.15x
SDGR
Schrodinger
-- 2.446 -- 3.17x
SLP
Simulations Plus
-- 1.776 -- 3.18x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ACCD
Accolade
$46.5M -$25.9M -29.12% -43.94% -24.61% -$10.6M
HQY
HealthEquity
$189M $44.3M 3.11% 4.59% 14.5% $62.2M
HSTM
HealthStream
$49.1M $4.7M 5.72% 5.72% 6.32% $4.3M
SDGR
Schrodinger
$64.1M -$20.7M -38.87% -38.87% -23.45% -$32M
SLP
Simulations Plus
$10.2M $126K 4.58% 4.58% 0.67% -$2.2M

Accolade vs. Competitors

  • Which has Higher Returns ACCD or HQY?

    HealthEquity has a net margin of -115.42% compared to Accolade's net margin of 8.46%. Accolade's return on equity of -43.94% beat HealthEquity's return on equity of 4.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACCD
    Accolade
    44.25% -$1.50 $522.4M
    HQY
    HealthEquity
    60.63% $0.30 $3.2B
  • What do Analysts Say About ACCD or HQY?

    Accolade has a consensus price target of $7.03, signalling upside risk potential of 0.22%. On the other hand HealthEquity has an analysts' consensus of $114.36 which suggests that it could grow by 34.73%. Given that HealthEquity has higher upside potential than Accolade, analysts believe HealthEquity is more attractive than Accolade.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACCD
    Accolade
    0 11 0
    HQY
    HealthEquity
    8 1 0
  • Is ACCD or HQY More Risky?

    Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HealthEquity has a beta of 0.617, suggesting its less volatile than the S&P 500 by 38.323%.

  • Which is a Better Dividend Stock ACCD or HQY?

    Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthEquity offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accolade pays -- of its earnings as a dividend. HealthEquity pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACCD or HQY?

    Accolade quarterly revenues are $105.1M, which are smaller than HealthEquity quarterly revenues of $311.8M. Accolade's net income of -$121.3M is lower than HealthEquity's net income of $26.4M. Notably, Accolade's price-to-earnings ratio is -- while HealthEquity's PE ratio is 77.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 1.23x versus 6.28x for HealthEquity. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACCD
    Accolade
    1.23x -- $105.1M -$121.3M
    HQY
    HealthEquity
    6.28x 77.87x $311.8M $26.4M
  • Which has Higher Returns ACCD or HSTM?

    HealthStream has a net margin of -115.42% compared to Accolade's net margin of 6.59%. Accolade's return on equity of -43.94% beat HealthStream's return on equity of 5.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACCD
    Accolade
    44.25% -$1.50 $522.4M
    HSTM
    HealthStream
    66.17% $0.16 $359.4M
  • What do Analysts Say About ACCD or HSTM?

    Accolade has a consensus price target of $7.03, signalling upside risk potential of 0.22%. On the other hand HealthStream has an analysts' consensus of $35.00 which suggests that it could grow by 10.94%. Given that HealthStream has higher upside potential than Accolade, analysts believe HealthStream is more attractive than Accolade.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACCD
    Accolade
    0 11 0
    HSTM
    HealthStream
    2 4 0
  • Is ACCD or HSTM More Risky?

    Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HealthStream has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.556%.

  • Which is a Better Dividend Stock ACCD or HSTM?

    Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream offers a yield of 0.37% to investors and pays a quarterly dividend of $0.03 per share. Accolade pays -- of its earnings as a dividend. HealthStream pays out 17.01% of its earnings as a dividend. HealthStream's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ACCD or HSTM?

    Accolade quarterly revenues are $105.1M, which are larger than HealthStream quarterly revenues of $74.2M. Accolade's net income of -$121.3M is lower than HealthStream's net income of $4.9M. Notably, Accolade's price-to-earnings ratio is -- while HealthStream's PE ratio is 47.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 1.23x versus 3.30x for HealthStream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACCD
    Accolade
    1.23x -- $105.1M -$121.3M
    HSTM
    HealthStream
    3.30x 47.80x $74.2M $4.9M
  • Which has Higher Returns ACCD or SDGR?

    Schrodinger has a net margin of -115.42% compared to Accolade's net margin of -45.54%. Accolade's return on equity of -43.94% beat Schrodinger's return on equity of -38.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACCD
    Accolade
    44.25% -$1.50 $522.4M
    SDGR
    Schrodinger
    72.61% -$0.55 $421.4M
  • What do Analysts Say About ACCD or SDGR?

    Accolade has a consensus price target of $7.03, signalling upside risk potential of 0.22%. On the other hand Schrodinger has an analysts' consensus of $32.09 which suggests that it could grow by 47.21%. Given that Schrodinger has higher upside potential than Accolade, analysts believe Schrodinger is more attractive than Accolade.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACCD
    Accolade
    0 11 0
    SDGR
    Schrodinger
    6 3 0
  • Is ACCD or SDGR More Risky?

    Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Schrodinger has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.426%.

  • Which is a Better Dividend Stock ACCD or SDGR?

    Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accolade pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACCD or SDGR?

    Accolade quarterly revenues are $105.1M, which are larger than Schrodinger quarterly revenues of $88.3M. Accolade's net income of -$121.3M is lower than Schrodinger's net income of -$40.2M. Notably, Accolade's price-to-earnings ratio is -- while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 1.23x versus 7.63x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACCD
    Accolade
    1.23x -- $105.1M -$121.3M
    SDGR
    Schrodinger
    7.63x -- $88.3M -$40.2M
  • Which has Higher Returns ACCD or SLP?

    Simulations Plus has a net margin of -115.42% compared to Accolade's net margin of 1.09%. Accolade's return on equity of -43.94% beat Simulations Plus's return on equity of 4.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACCD
    Accolade
    44.25% -$1.50 $522.4M
    SLP
    Simulations Plus
    54% $0.01 $184.7M
  • What do Analysts Say About ACCD or SLP?

    Accolade has a consensus price target of $7.03, signalling upside risk potential of 0.22%. On the other hand Simulations Plus has an analysts' consensus of $49.40 which suggests that it could grow by 93.31%. Given that Simulations Plus has higher upside potential than Accolade, analysts believe Simulations Plus is more attractive than Accolade.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACCD
    Accolade
    0 11 0
    SLP
    Simulations Plus
    6 1 0
  • Is ACCD or SLP More Risky?

    Accolade has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Simulations Plus has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.602%.

  • Which is a Better Dividend Stock ACCD or SLP?

    Accolade has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 0.94% to investors and pays a quarterly dividend of $0.06 per share. Accolade pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ACCD or SLP?

    Accolade quarterly revenues are $105.1M, which are larger than Simulations Plus quarterly revenues of $18.9M. Accolade's net income of -$121.3M is lower than Simulations Plus's net income of $206K. Notably, Accolade's price-to-earnings ratio is -- while Simulations Plus's PE ratio is 63.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accolade is 1.23x versus 6.97x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACCD
    Accolade
    1.23x -- $105.1M -$121.3M
    SLP
    Simulations Plus
    6.97x 63.89x $18.9M $206K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Progressive Stock Go Down?
Why Did Progressive Stock Go Down?

Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…

Why Did StoneCo Stock Go Up So Much?
Why Did StoneCo Stock Go Up So Much?

Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…

Is Tenable Stock a Buy, Sell or Hold?
Is Tenable Stock a Buy, Sell or Hold?

Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…

Stock Ideas

Buy
55
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Sell
50
RGC alert for Mar 24

Regencell Bioscience Holdings [RGC] is down 28.36% over the past day.

Buy
54
TNXP alert for Mar 24

Tonix Pharmaceuticals Holding [TNXP] is up 32.39% over the past day.

Sell
36
VMI alert for Mar 24

Valmont Industries [VMI] is up 4.67% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock